Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.49
USD
|
0.00%
|
|
-6.29%
|
-7.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
141
|
147.9
|
126.9
|
35.13
|
46.39
|
43.56
|
-
|
Enterprise Value (EV)
1 |
141
|
147.9
|
126.9
|
35.13
|
46.39
|
43.56
|
43.56
|
P/E ratio
|
-16.7
x
|
-15.8
x
|
-9.62
x
|
-3.62
x
|
-6.71
x
|
-2.26
x
|
-1.66
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
83.9
x
|
92.3
x
|
52.8
x
|
12
x
|
16
x
|
10.4
x
|
7.14
x
|
EV / Revenue
|
83.9
x
|
92.3
x
|
52.8
x
|
12
x
|
16
x
|
10.4
x
|
7.14
x
|
EV / EBITDA
|
-
|
-
|
-11,392,519
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-11,254,620
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
27,213
|
27,482
|
28,079
|
28,563
|
28,811
|
29,237
|
-
|
Reference price
2 |
5.180
|
5.380
|
4.520
|
1.230
|
1.610
|
1.490
|
1.490
|
Announcement Date
|
3/30/20
|
3/30/21
|
3/29/22
|
3/29/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
1.681
|
1.602
|
2.404
|
2.93
|
2.899
|
4.2
|
6.1
|
EBITDA
|
-
|
-
|
-11.14
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.283
|
-10.03
|
-14.73
|
-10.17
|
-8.23
|
-23.2
|
-28.8
|
Operating Margin
|
-552.18%
|
-625.85%
|
-612.67%
|
-346.92%
|
-283.9%
|
-552.38%
|
-472.13%
|
Earnings before Tax (EBT)
1 |
-8.298
|
-9.294
|
-13.07
|
-9.735
|
-6.795
|
-22.7
|
-28.3
|
Net income
1 |
-8.308
|
-9.325
|
-13.07
|
-9.735
|
-6.795
|
-22.7
|
-31.3
|
Net margin
|
-494.2%
|
-582.13%
|
-543.73%
|
-332.23%
|
-234.42%
|
-540.48%
|
-513.11%
|
EPS
2 |
-0.3100
|
-0.3400
|
-0.4700
|
-0.3400
|
-0.2400
|
-0.6600
|
-0.9000
|
Free Cash Flow
|
-
|
-
|
-11.28
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-469.12%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
3/30/21
|
3/29/22
|
3/29/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
0.6929
|
0.3133
|
0.6484
|
0.6586
|
0.8796
|
0.7437
|
-
|
0.8372
|
0.3971
|
0.6865
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.324
|
-4.216
|
-2.745
|
-3.318
|
-1.863
|
-2.24
|
-
|
-2.29
|
-1.72
|
-2.169
|
Operating Margin
|
-479.7%
|
-1,345.65%
|
-423.27%
|
-503.83%
|
-211.85%
|
-301.13%
|
-
|
-273.6%
|
-433.21%
|
-315.89%
|
Earnings before Tax (EBT)
1 |
-1.715
|
-4.214
|
-2.492
|
-3.288
|
-1.809
|
-2.146
|
-
|
-2.153
|
-1.614
|
-2.072
|
Net income
1 |
-1.715
|
-4.214
|
-2.492
|
-3.288
|
-1.809
|
-2.146
|
-0.9564
|
-2.153
|
-1.614
|
-2.072
|
Net margin
|
-247.54%
|
-1,345.03%
|
-384.26%
|
-499.28%
|
-205.68%
|
-288.6%
|
-
|
-257.17%
|
-406.55%
|
-301.77%
|
EPS
2 |
-0.0600
|
-0.1500
|
-0.0900
|
-0.1200
|
-0.0600
|
-0.0700
|
-0.0300
|
-0.0700
|
-0.0600
|
-0.0800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/29/22
|
5/12/22
|
8/10/22
|
11/10/22
|
3/29/23
|
5/10/23
|
8/9/23
|
11/8/23
|
3/28/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-11.3
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
3/30/21
|
3/29/22
|
3/29/23
|
3/28/24
|
-
|
-
|
Last Close Price
1.49
USD Average target price
7.5
USD Spread / Average Target +403.36% Consensus |
1st Jan change
|
Capi.
|
---|
| -7.45% | 43.56M | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|